EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

A Japanese case of VEXAS syndrome after COVID-19 vaccination: Comparison with previously reported cases

Yui Miyagi, Hiroshi Kobayashi iD, Yoshihiro Umebayashi, Akira Okimura, Munehide Nakatsugawa, Ayaka Maeda, Yohei Kirino, Akiko Aoki

Modern Rheumatology Case Reports · 2025

DOI: 10.1093/mrcr/rxae054 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2025. Verfasst von Yui Miyagi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Ubiquitin-Activating Enzymes, Hereditary Autoinflammatory Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome is a novel adult-onset autoinflammatory disorder caused by variants in the UBA1 gene. Here, we report a Japanese case of VEXAS syndrome in which symptoms began 1 day after the second booster dose of a coronavirus disease 2019 (COVID-19) messenger ribonucleic acid vaccine, and a UBA1 variant was subsequently confirmed. Combined with the three cases reported thus far, this suggests that the COVID-19 vaccine may be one of the triggers for development of VEXAS syndrome in Asian populations. Since COVID-19 vaccines have been reported to be associated with various autoinflammatory and autoimmune diseases, it is important to continue to pay close attention to the relationship between COVID-19 vaccines and VEXAS syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19Ubiquitin-Activating EnzymesHereditary Autoinflammatory DiseasesHumansMaleJapanSARS-CoV-2AdultSyndromeFemaleMiddle AgedEast Asian PeopleMyelodysplastic SyndromesSkin Diseases, Genetic

Stichwörter der Autor:innen

COVID-19VEXAS syndromerelationshipvaccine

Substanzen

COVID-19 VaccinesUbiquitin-Activating EnzymesUBA1 protein, human

Autor:innen und Institutionen

  • Department of Rheumatology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
  • Department of Dermatology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
  • Department of Pathology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
  • Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

ORCID-Profile: Hiroshi Kobayashi

Zitieren

APA

Miyagi, Y., Kobayashi, H., Umebayashi, Y., Okimura, A., Nakatsugawa, M., Maeda, A., Kirino, Y., & Aoki, A. (2025). A Japanese case of VEXAS syndrome after COVID-19 vaccination: Comparison with previously reported cases. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxae054

Vancouver

Miyagi Y, Kobayashi H, Umebayashi Y, Okimura A, Nakatsugawa M, Maeda A, et al. A Japanese case of VEXAS syndrome after COVID-19 vaccination: Comparison with previously reported cases. Modern Rheumatology Case Reports. 2025. doi:10.1093/mrcr/rxae054

BibTeX
@article{Miyagi2025,
  author = {Miyagi, Yui and Kobayashi, Hiroshi and Umebayashi, Yoshihiro and Okimura, Akira and Nakatsugawa, Munehide and Maeda, Ayaka and Kirino, Yohei and Aoki, Akiko},
  title = {A Japanese case of VEXAS syndrome after COVID-19 vaccination: Comparison with previously reported cases},
  journal = {Modern Rheumatology Case Reports},
  year = {2025},
  doi = {10.1093/mrcr/rxae054}
}
Kostenlos starten →